|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400081091 |
|
最近更新日期: Date of Last Refreshed on: |
2024-02-22 10:37:02 |
|
注册时间: Date of Registration: |
2024-02-22 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
电针治疗轻度阻塞性睡眠呼吸障碍合并失眠的临床研究 |
|
Public title: |
Clinical study of electroacupuncture in the treatment of mild obstructive sleep apnea combined with insomnia |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
电针治疗轻度阻塞性睡眠呼吸障碍合并失眠的临床研究 |
|
Scientific title: |
Clinical study of electroacupuncture in the treatment of mild obstructive sleep apnea combined with insomnia |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
蔡粤娟 |
研究负责人: |
段玉婷 |
|
Applicant: |
Yuejuan Cai |
Study leader: |
Yuting Duan |
|
申请注册联系人电话: Applicant telephone: |
+86 181 7371 4078 |
研究负责人电话:
Study leader's |
+86 187 0200 9530 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
cyj11292023@163.com |
研究负责人电子邮件: Study leader's E-mail: |
18702009530@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广州市天河区天坤三路95号 |
研究负责人通讯地址: |
广州市天河区天坤三路95号 |
|
Applicant address: |
No.95, Tiankun 3rd Road, Tianhe District, Guangzhou, China |
Study leader's address: |
No.95, Tiankun 3rd Road, Tianhe District, Guangzhou, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
广州中医药大学附属广州中医医院 |
||
|
Applicant's institution: |
The Affiliated Guangzhou Hospital of TCM of Guangzhou University of Chinese Medicine |
||
|
研究负责人所在单位: |
广州医科大学附属中医医院 |
||
|
Affiliation of the Leader: |
The Affiliated TCM Hospital of Guangzhou Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024NK006 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
广州医科大学附属中医医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the Affiliated TCM Hospital of Guangzhou Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-01-15 00:00:00 | ||
|
伦理委员会联系人: |
李若薇 |
||
|
Contact Name of the ethic committee: |
Ruowei Li |
||
|
伦理委员会联系地址: |
广州市天河区天坤三路95号 |
||
|
Contact Address of the ethic committee: |
No.95, Tiankun 3rd Road, Tianhe District, Guangzhou, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 8122 2775 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
广州医科大学附属中医医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Affiliated TCM Hospital of Guangzhou Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广州市天河区天坤三路95号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.95, Tiankun 3rd Road, Tianhe District, Guangzhou, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
2023广州医科大学科研能力提升计划重大临床研究项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
2023 Major Clinical Research Project of Guangzhou Medical University Research Capacity Enhancement Program |
||||||||||||||||||||||
|
研究疾病: |
轻度阻塞性睡眠呼吸障碍合并失眠 |
||||||||||||||||||||||
|
Target disease: |
Mild obstructive sleep apnea combined with insomnia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
IV期临床试验 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
观察电针干预对轻度阻塞性睡眠呼吸障碍合并失眠的临床疗效,为电针临床干预及科学研究提供依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
To observe the clinical efficacy of electroacupuncture intervention on mild obstructive sleep apnea combined with insomnia, and to provide a basis for electroacupuncture clinical intervention and scientific research. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①符合《成人阻塞性睡眠呼吸暂停多学科诊疗指南》中阻塞性睡眠呼吸障碍(OSA)的诊断标准; ②符合轻度阻塞性睡眠呼吸障碍的分类标准,即睡眠呼吸暂停低通气指数(AHI)为5-15次/h; ③符合睡眠国际分类第3版(ICSD-3)慢性失眠诊断标准; ④匹兹堡睡眠质量指数(PSQI)为5-15分; ⑤年龄为18~65周岁; ⑥对试验知情并签署知情同意书者。 |
||||||||||||||||||||||
|
Inclusion criteria |
①Meet the diagnostic criteria for obstructive sleep apnea (OSA) in the Multidisciplinary Diagnostic and Treatment Guidelines for Obstructive Sleep Apnea in Adults; ②Meet the classification criteria for mild obstructive sleep apnea disorder, i.e., a sleep apnea hypoventilation index (AHI) of 5-15 breaths/h; ③Meeting the diagnostic criteria for chronic insomnia according to the International Classification of Sleep, 3rd edition (ICSD-3); ④Pittsburgh Sleep Quality Index (PSQI) score of 5-15; ⑤Age 18-65 years old; ⑥Those who were informed about the trial and signed the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
①3个月内检查发现鼻咽呼吸道器质性病变; ②既往曾行呼吸道局部手术治疗者; ③有晕针史; ④妊娠或计划妊娠以及哺乳期妇女; ⑤合并严重肝、肾功能不全、心脑血管疾病、精神障碍、恶性肿瘤、凝血障碍、严重胃肠疾病者。 ⑥器质性失眠者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
①Organic lesions of the nasopharyngeal respiratory tract found on examination within 3 months; ②Those who have previously undergone localized surgical treatment of the respiratory tract; ③History of needle-sickness; ④Organic lesions of the nasopharyngeal respiratory tract detected in the examination within 3 months ⑤Combined severe liver and renal insufficiency, cardiovascular and cerebrovascular diseases, mental disorders, malignant tumors, coagulation disorders, and severe gastrointestinal diseases. ⑥Organic insomnia. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-01-31 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-03-01 00:00:00 至 To 2026-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究采用中心随机化方法,根据独立统计学家使用SPSS26.0生成的随机序列对患者进行分组,然后以1:1的比例随机分配到干预组和对照组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
In this study, central randomization will be used and patients will be grouped according to a random sequence generated by an independent statistician using SPSS 26.0 and then randomly assigned to the intervention and control groups in a ratio of 1:1. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
严格实施评价者盲法,评价者对分组方案不知情,且不参与病人的医疗、护理及干预工作。 |
|
Blinding: |
Evaluator blinding was strictly enforced, and evaluators were unaware of the grouping scheme and were not involved in the patient's medical treatment, care, and interventions. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究中所涉及的原始数据包括在文章及补充材料中,进一步的询问可以直接联系通讯作者。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The raw data involved in the study are included in the article and in the supplementary materials, and further inquiries can be directed to the corresponding authors |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
1.所有进入试验的患者均参照CRF的填写说明,认真、详细记录CRF中的所有项目并采用双人核对录入。 2.采用EpiData 3.1建立数据库。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
1. All patients entering the trial referred to the instructions for completing the CRF, carefully and in detail recorded all items in the CRF and used two-person checking entry. 2. EpiData 3.1 was used to establish the database. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |